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In the treatment of bronchial asthma, inhaled 
therapy with bronchodilators and     corticosteroids 
represents the basis for acute and long-term 
management. Drug therapy in asthma is predominantly 
by pressurized metered dose inhalers. The impact of 
treatment on the disease morbidity and mortality 
depends to a large extent on appropriate delivery of 
drugs to the lungs by means of a spacer device and on 
the continuity of treatment. Poor compliance with 
medication is a well known problem in conditions which 
require long-term treatment. This is especially so in 
asthma where initial improvement may be followed by 
longer remission and a tendency to stop treatment. 
Compliance is "the extent to which a  person’s  behaviour  
(in terms of taking medications, following diets, or 
executing lifestyle changes) coincides with medical or 
health advice." 1. Compliance with preventive therapy 
such as inhaled corticosteroids (ICS), the effects of 
which are seen over a period of weeks, may be less than 
compliance with drugs that relieve asthma symptoms 
more rapidly such as bronchodilators. To our knowledge 
there are no previous studies which have assessed the 
prevalence of non-compliance with inhaled 
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Aims 
The aim of this audit was to assess and quantify the 
prevalence of poor compliance with prescribed inhaled 
corticosteroid medication in Maltese asthmatic children. 
Also the practice and prevalence of stopping therapy in 
the summer months will also be assessed. Finally the use 
of a spacer device will be documented and compared 




One hundred and thirty one children between seven 
and  fifteen  years  of  age  attending  a  children’s  out-
patient clinic between December 2013 and March 2014 
were assessed. The audit was questionnaire-based 
(figure 1). Questions asked form part of the routine 
assessment and management of asthmatic children 
attending for regular visits and for this reason, ethics 
committee approval was not required. Patients recruited 
attended outpatients for routine follow-up and were 
under the care of a single consultant. Results were 
compared to an identical audit that was carried out in 
one hundred and twenty four children attending the same 
clinic during 2008. 
 
Results 
Questionnaires were completed for 131 children 
with a diagnosis of chronic bronchial asthma attending 
the paediatric outpatient department between December 
2013 and March 2014. Results were compared to those 
from an identical audit carried out on 124 children in 
2008. 162 were male (63%) and 93 were female (37%). 
124 were between the ages of 7 and 10 years (49%) and 
131 were between 11 and 15 years of age (51%).  
 
Use of spacing device for delivery 
The use of a spacer device in the administration of 
inhaled corticosteroids was recorded as 98% in 2008 and 
99% in 2014.  
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Figure 1: Sample of questionnaire 
Age bracket  7-10  11-14  
Sex  Male  Female  
Do you make use of a spacer device whilst consuming your MDI?  Always  Most times  Sometimes  Never  Not applicable (for dry powder inhalers only)  
If not always making use of spacer device – Why?  Believe to have enough co-ordination to do without device  Too unsightly or bulky to use and carry around  Believe it makes no difference  Indifferent  
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Figure 1: Sample of questionnaire (cont.) 
If not always complying with treatment regimen – Why? Do not feel it is necessary Fear of side effects Indifferent 
Parental impression: Do you think that your child takes his preventative 
treatment regularly? Always Most times Sometimes Never 
Do you stop you prophylactic inhalers during the summer months? Yes No 
If you do not stop your inhaler treatment, do you reduce the dose? Yes No 
If you do stop your inhaler treatment – Why? Advised by doctor 
 
Compliance with prophylaxis 
When asked about the regular use of prophylactic 
ICS, 90% claimed they always took their treatment. This 
was comparable to a compliance rate of 92% recorded in 
2008. 
Those patients who were non-compliant with 
regular use of ICS cited that they did not feel treatment 
was necessary in 36% in 2008 and 24% in 2014. The 
rest of the patients that were non-compliant were 
indifferent. 
The parental impression of the regularity of 
treatment in their children compared well to the claims 
of the children themselves.  
 
Stopping prophylaxis in summer 
When asked if ICS were stopped during the 
summer months, 23% said that they stop their  
 
 
prophylaxis in 2008. An improvement was noted in 2014 
when the rate of patients who stopped treatment 
decreased to 18%. The commonest reason cited for 
stopping ICS in summer was that patients felt better and 
saw no benefit to continue. A significant percentage of 
children either stopped their treatment in summer 
following medical advice (28% in 2008, 21% in 2014) 
or reduced the dose of ICS (18% in 2008, 7% in 2014). 
 
  Relation of compliance with age of patient 
Compliance in patients in the 11 -15 year old 




Compliance, or adherence, as it relates to health 
care is the extent to which a person's behaviour coincides 
with medical or health advice. Medication compliance is 
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critical for all aspects of paediatrics, specifically in 
successful treatment, disease prevention, and health 
promotion. 3, 4, 5 Compliance depends on the patient's and 
physician's committing to the same objectives. It is 
unfortunate that numerous studies and physician 
accounts reveal difficulties in achieving compliance with 
paediatric medication therapy. Medication compliance in 
paediatric patients ranges from 11% to 93%.5 Poor 
compliance places children at risk for problems such as 
continued disease, complicates the physician-patient 
relationship, and prevents accurate assessment of the 
quality of care provided.  
This audit demonstrates that multiple factors may 
come between a prescription for an inhaled 
corticosteroid and the arrival of that medicine to its 
target organ, the lung. These factors have to be 
considered when assessing response to treatment. 
Frequently physicians fail to assess the impact that poor 
compliance has on disease control and will resort to the 
use of stronger and frequently more expensive 
medications with an aim of improving control. The 
patient or his carer, in the case of young children, should 
be directly questioned regarding compliance before 
major changes to therapy are made. 
Patients fail to comply with asthma medication for 
a variety of reasons 6, 7. These range from physical 
inability to use an inhaler, through simple forgetfulness, 
to a conscious decision not to use medication as 
prescribed due to internal or cultural health beliefs or 
socioeconomic factors. In some patients, poor self-care 
because of deep-rooted psychological factors (i.e. factors 
of which patients have only limited awareness) can 
affect compliance 8, 9, 10. Poor doctor-patient 
communication can be the cause in many other 
individuals. Patient indifference to administration of ICS 
was and still is a significant factor in non-compliance. 
The high percentage of use of spacer devices as well as 
the significant drop in the percentage of patients who 
decrease the dose of their treatment during the summer 
months is encouraging. The comparable high 
compliance rate in the older age group was surprising 
and reassuring. This may be a result of a non-patronising 
attitude with older asthmatic children and ongoing 
education of our asthmatics from an early age. We 
believe that the relatively good compliance rates 
observed locally are the result of close follow-up of 
asthmatic children on a regular basis and the repeated 
assessment of the technique of medication 
administration. Although the number of patients was 
relatively small, the similar results from both audits 
carried out several years apart represent a true picture of 
the local situation. 
 
Conclusion 
There is no single solution that will improve 
compliance in all patients. Simplifying the regimen or 
providing memory aids will be sufficient for some 
patients, while education will be more appropriate for 
others. Doctors can also use a range of communication 
skills to improve the way in which they present 
information, motivate patients and reinforce progress. 
These approaches, together with respect for patients' 
health beliefs and involving them in treatment decisions, 
can help foster an atmosphere of mutual responsibility 
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